Sorrento Updates on Immunotherapies, ‘Off-The-Shelf’ Cell Therapy Manufacture

Sorrento Therapeutics, Inc. (NASDAQ: SRNE, ‘Sorrento’) announces today that its Chairman and CEO, Dr. Henry Ji will be discussing the progress made, including innovative higher potency Dimeric Antigen Receptor (‘DAR’) technology and allogeneic knock-out/knock-in (‘KOKI’) cell therapy manufacturing advances related to its CD38 immunotherapies at upcoming industry conferences, investor conferences and investor meetings.

The reference presentation in support of those update discussions has been uploaded to the Sorrento investor relations website and was filed today with the Securities and Exchange Commission (‘SEC’) on a Current Report on Form 8-K.

Key progress update areas that will be discussed include: Clinical Proof-of-concept Study for Anti-CD38 Autologous CAR-T Cell Therapy.

https://www.marketscreener.com/SORRENTO-THERAPEUTICS-INC-14708339/news/Sorrento-Therapeutics-Provides-Updates-on-CD38-Immunotherapies-and-Implementation-of-Disruptive-GM-28786667/